Nymox Pharma (NYMX) Ramps to Session Highs Following Fexapotide Phase 3 Data
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Nymox Pharma (Nasdaq: NYMX) shares are trading to session highs. The stock is up over 75 percent on the session after the company announced successful new study results from the long-term blinded placebo crossover group from the U.S. Phase 3 trials for fexapotide, the Company's lead compound in late stage development for enlarged prostate (BPH) and for localized prostate cancer.
For more color, click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Neovasc (NVCN) Climbs to Session High, Shares Up 125%
- Costco Wholesale Corp (COST) weekly volatility increases into Q1 and outlook
- Ciena (CIEN) calls active on 2.5 calls to 1 put into Q4
Create E-mail Alert Related CategoriesMomentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!